These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 31046540)

  • 1. Association of absolute lymphocyte count and peripheral blood lymphocyte subsets percentage with minimal residual disease at the end of induction in pediatric B cell acute lymphoblastic leukemia.
    Pushpam D; Rajput N; Chopra A; Vishnubhatla S; Kumari M; Kumar R; Bakhshi S
    Pediatr Hematol Oncol; 2019 Apr; 36(3):138-150. PubMed ID: 31046540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ratio of absolute lymphocyte count at interim of therapy to absolute lymphocyte count at diagnosis predicts survival in childhood B-lineage acute lymphoblastic leukemia.
    Cheng Y; Luo Z; Yang S; Jia M; Zhao H; Xu W; Tang Y
    Leuk Res; 2015 Feb; 39(2):144-50. PubMed ID: 25542697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absolute Lymphocyte Count at the End of Induction as a Surrogate Marker for Minimal Residual Disease in T-cell Acute Lymphoblastic Leukemia.
    Pushpam D; Chopra A; Sreenivas V; Kumar R; Bakhshi S
    Indian Pediatr; 2019 May; 56(5):381-383. PubMed ID: 30898988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absolute lymphocyte count is associated with minimal residual disease level in childhood B-cell precursor acute lymphoblastic leukemia.
    Shen HQ; Feng JH; Tang YM; Song H; Yang SL; Shi SW; Xu WQ
    Leuk Res; 2013 Jun; 37(6):671-4. PubMed ID: 23453285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absolute lymphocyte counts refine minimal residual disease-based risk stratification in childhood acute lymphoblastic leukemia.
    Rabin KR; Gramatges MM; Borowitz MJ; Palla SL; Shi X; Margolin JF; Zweidler-McKay PA
    Pediatr Blood Cancer; 2012 Sep; 59(3):468-74. PubMed ID: 22102553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eleven-marker 10-color flow cytometric assessment of measurable residual disease for T-cell acute lymphoblastic leukemia using an approach of exclusion.
    Tembhare PR; Chatterjee G; Khanka T; Ghogale S; Badrinath Y; Deshpande N; Panda D; Patkar NV; Narula G; Girase K; Verma S; Sanyal M; Sriram HN; Banavali S; Gujral S; Subramanian PG
    Cytometry B Clin Cytom; 2021 Jul; 100(4):421-433. PubMed ID: 32812702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD304/neuropilin-1 is a very useful and dependable marker for the measurable residual disease assessment of B-cell precursor acute lymphoblastic leukemia.
    Gudapati P; Khanka T; Chatterjee G; Ghogale S; Badrinath Y; Deshpande N; Patil J; Narula G; Shetty D; Banavali S; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
    Cytometry B Clin Cytom; 2020 Jul; 98(4):328-335. PubMed ID: 31944572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absolute Lymphocyte Count (ALC) after Induction Treatment Predicts Survival of Pediatric Patients with Acute Lymphoblastic Leukemia.
    Farkas T; Müller J; Erdelyi DJ; Csoka M; Kovacs GT
    Pathol Oncol Res; 2017 Oct; 23(4):889-897. PubMed ID: 28138921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of minimal residual disease on relapse in childhood acute lymphoblastic leukemia: Lessons learnt from a tertiary cancer center in India.
    Mishra V; Jain S; Anand V; Malhotra P; Tejwani N; Kapoor G
    Pediatr Hematol Oncol; 2023; 40(6):517-528. PubMed ID: 36930957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of minimal residual disease in childhood B-acute lymphoblastic leukemia by 4-color flowcytometry.
    Baraka A; Sherief LM; Kamal NM; Shorbagy SE
    Int J Hematol; 2017 Jun; 105(6):784-791. PubMed ID: 28324281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal residual disease level determined by flow cytometry provides reliable risk stratification in adults with T-cell acute lymphoblastic leukaemia.
    Wang H; Zhou Y; Huang X; Zhang Y; Qian J; Li J; Li C; Li X; Lou Y; Zhu Q; Huang Y; Meng H; Yu W; Tong H; Jin J; Zhu HH
    Br J Haematol; 2021 Jun; 193(6):1096-1104. PubMed ID: 33764511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The significance of peripheral blood minimal residual disease to predict early disease response in patients with B-cell acute lymphoblastic leukemia.
    Setiadi A; Owen D; Tsang A; Milner R; Vercauteren S
    Int J Lab Hematol; 2016 Oct; 38(5):527-34. PubMed ID: 27339737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of CD304/neuropilin-1 in adult b-cell lymphoblastic leukemia/lymphoma and its utility for the measurable residual disease assessment.
    Chatterjee G; Dudakia V; Ghogale S; Deshpande N; Girase K; Chaturvedi A; Shetty D; Senger M; Jain H; Bagal B; Bonda A; Punatar S; Gokarn A; Khattry N; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
    Int J Lab Hematol; 2021 Oct; 43(5):990-999. PubMed ID: 33432783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of absolute lymphocyte counts at the end of remission induction in childhood acute lymphoblastic leukemia.
    Rubnitz JE; Campbell P; Zhou Y; Sandlund JT; Jeha S; Ribeiro RC; Inaba H; Bhojwani D; Relling MV; Howard SC; Campana D; Pui CH
    Cancer; 2013 Jun; 119(11):2061-6. PubMed ID: 23456849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL.
    Wood B; Wu D; Crossley B; Dai Y; Williamson D; Gawad C; Borowitz MJ; Devidas M; Maloney KW; Larsen E; Winick N; Raetz E; Carroll WL; Hunger SP; Loh ML; Robins H; Kirsch I
    Blood; 2018 Mar; 131(12):1350-1359. PubMed ID: 29284596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia.
    Gökbuget N; Dombret H; Giebel S; Bruggemann M; Doubek M; Foà R; Hoelzer D; Kim C; Martinelli G; Parovichnikova E; Rambaldi A; Ribera JM; Schoonen M; Stieglmaier JM; Zugmaier G; Bassan R
    Hematology; 2019 Dec; 24(1):337-348. PubMed ID: 30757960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flow-cytometric minimal residual disease monitoring in blood predicts relapse risk in pediatric B-cell precursor acute lymphoblastic leukemia in trial AIEOP-BFM-ALL 2000.
    Schumich A; Maurer-Granofszky M; Attarbaschi A; Pötschger U; Buldini B; Gaipa G; Karawajew L; Printz D; Ratei R; Conter V; Schrappe M; Mann G; Basso G; Dworzak MN;
    Pediatr Blood Cancer; 2019 May; 66(5):e27590. PubMed ID: 30561169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular genetic profile in BCR-ABL1 negative pediatric B-cell acute lymphoblastic leukemia can further refine outcome prediction in addition to that by end-induction minimal residual disease detection.
    Gupta SK; Bakhshi S; Chopra A; Kamal VK
    Leuk Lymphoma; 2018 Aug; 59(8):1899-1904. PubMed ID: 29199525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children's Oncology Group trial AALL1231.
    Hayashi RJ; Hermiston ML; Wood BL; Teachey DT; Devidas M; Chen Z; Annett RD; Asselin BL; August K; Cho S; Dunsmore KP; Freedman JL; Galardy PJ; Harker-Murray P; Horton TM; Jaju A; Lam A; Messinger YH; Miles RR; Okada M; Patel S; Schafer ES; Schechter T; Shimano KA; Singh N; Steele A; Sulis ML; Vargas SL; Winter SS; Wood C; Zweidler-McKay PA; Loh ML; Hunger SP; Raetz EA; Bollard CM; Allen CE
    Blood; 2024 May; 143(20):2053-2058. PubMed ID: 38457359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early (Day 15 Post Diagnosis) Peripheral Blood Assessment of Measurable Residual Disease in Flow Cytometry is a Strong Predictor of Outcome in Childhood B-Lineage Lymphoblastic Leukemia.
    Loosveld M; Nivaggioni V; Arnoux I; Bernot D; Michel G; Béné MC; Eveillard M
    Cytometry B Clin Cytom; 2019 Mar; 96(2):128-133. PubMed ID: 30734503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.